Pathogenesis of systemic sclerosis—current concept and emerging treatments

Medicine and Dentistry

• Systemic Scleroderma 100%
• Autoantibody 83%
• Endothelial Cell 66%
• Pathogenesis 50%
• Receptor 33%
• Vascular Disease 33%
• Fibrosis 33%
• Emerging Treatment 33%
• Cytokine 16%
• Patient 16%
• Diagnosis 16%
• Therapeutic Procedure 16%
• Diseases 16%
• Biological Marker 16%
• Topoisomerase 16%
• Fibroblast 16%
• Programmed Cell Death 16%
• Inflammatory Cell 16%
• Angiotensin II 16%
• Mortality 16%
• B Cell 16%
• Autoimmunity 16%
• Collagen 16%
• Interleukin 13 16%
• Interleukin 4 16%
• Interleukin 6 16%
• Cytokine Production 16%
• Endothelin 16%
• Cellular Infiltration 16%
• Connective Tissue Growth Factor 16%
• Centromere Antibody 16%
• Anti-Centromere Antibodies 16%
• Transforming Growth Factor 16%
• Myofibroblast 16%